ACRS
Aclaris Therapeutics, Inc.
Aclaris Therapeutics (ACRS) Q2 2026 earnings
Published Aug 6, 2026
AI summary
- Revenue $1.63M, down 8.3% from $1.78M a year ago.
- GAAP EPS −$0.15 beat the −$0.16 consensus by $0.01, down from −$0.13 a year ago.
- Aclaris reported second quarter 2026 revenue of $1.6 million, down from $1.8 million in the prior year period.
- The net loss for the quarter widened to $21.5 million compared to $15.4 million in the second quarter of 2025.
- Research and development expenses rose to $18.1 million, driven by clinical development for ATI-052 and ATI-9494.
Results vs analyst consensus
Revenue
Reported
$1.63M
Consensus not captured before release
−8.3% YoY
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.15
Consensus −$0.16
Beat by $0.01GAAP EPS: −$0.15
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company is a clinical-stage biopharmaceutical firm with no approved products and ongoing net losses.
- Operating expenses increased significantly due to higher R&D investment in the company's pipeline.
Read original report
Source: Aclaris Therapeutics, Inc. press release · SEC Form 8-K exhibit 99.1